Current and historical daily PE Ratio for GNTLF (
Genetic Technologies Ltd
) from 2002 to May 18 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Genetic Technologies stock (GNTLF) PE ratio as of May 18 2024 is 2.5.
More Details
Genetic Technologies Ltd (GNTLF) PE Ratio (TTM) Chart
Genetic Technologies Ltd (GNTLF) PE Ratio (TTM) Historical Data
View and export this data going back to 2002. Start your Free Trial
Total 1230
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Genetic Technologies PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-19 | 2.2 | 2024-03-15 | 2.2 |
| 2024-05-17 | 2.2 | 2024-03-14 | 2.2 |
| 2024-05-16 | 2.2 | 2024-03-13 | 2.2 |
| 2024-05-15 | 2.2 | 2024-03-12 | 2.2 |
| 2024-05-14 | 2.2 | 2024-03-11 | 2.2 |
| 2024-05-13 | 2.2 | 2024-03-08 | 2.2 |
| 2024-05-10 | 2.2 | 2024-03-07 | 2.2 |
| 2024-05-09 | 2.2 | 2024-03-06 | 2.2 |
| 2024-05-08 | 2.2 | 2024-03-05 | 2.2 |
| 2024-05-07 | 2.2 | 2024-03-04 | 2.2 |
| 2024-05-06 | 2.2 | 2024-03-01 | 2.2 |
| 2024-05-03 | 2.2 | 2024-02-29 | 2.2 |
| 2024-05-02 | 2.2 | 2024-02-28 | 2.2 |
| 2024-05-01 | 2.2 | 2024-02-27 | 2.2 |
| 2024-04-30 | 2.2 | 2024-02-26 | 2.2 |
| 2024-04-29 | 2.2 | 2024-02-23 | 2.2 |
| 2024-04-26 | 2.2 | 2024-02-22 | 2.2 |
| 2024-04-25 | 2.2 | 2024-02-21 | 2.2 |
| 2024-04-24 | 2.2 | 2024-02-20 | 2.2 |
| 2024-04-23 | 2.2 | 2024-02-16 | 2.2 |
| 2024-04-22 | 2.2 | 2024-02-15 | 2.2 |
| 2024-04-19 | 2.2 | 2024-02-14 | 2.2 |
| 2024-04-18 | 2.2 | 2024-02-13 | 2.2 |
| 2024-04-17 | 2.2 | 2024-02-12 | 2.2 |
| 2024-04-16 | 2.2 | 2024-02-09 | 2.2 |
| 2024-04-15 | 2.2 | 2024-02-08 | 2.2 |
| 2024-04-12 | 2.2 | 2024-02-07 | 2.2 |
| 2024-04-11 | 2.2 | 2024-02-06 | 2.2 |
| 2024-04-10 | 2.2 | 2024-02-05 | 2.2 |
| 2024-04-09 | 2.2 | 2024-02-02 | 2.2 |
| 2024-04-08 | 2.2 | 2024-02-01 | 2.2 |
| 2024-04-05 | 2.2 | 2024-01-31 | 2.2 |
| 2024-04-04 | 2.2 | 2024-01-30 | 2.2 |
| 2024-04-03 | 2.2 | 2024-01-29 | 2.2 |
| 2024-04-02 | 2.2 | 2024-01-26 | 2.2 |
| 2024-04-01 | 2.2 | 2024-01-25 | 2.2 |
| 2024-03-28 | 2.2 | 2024-01-24 | 2.2 |
| 2024-03-27 | 2.2 | 2024-01-23 | 2.2 |
| 2024-03-26 | 2.2 | 2024-01-22 | 2.2 |
| 2024-03-25 | 2.2 | 2024-01-19 | 2.2 |
| 2024-03-22 | 2.2 | 2024-01-18 | 2.2 |
| 2024-03-21 | 2.2 | 2024-01-17 | 2.2 |
| 2024-03-20 | 2.2 | 2024-01-16 | 2.2 |
| 2024-03-19 | 2.2 | 2024-01-12 | 2.2 |
| 2024-03-18 | 2.2 | 2024-01-11 | 2.2 |
Genetic Technologies Ltd (GNTLF) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Genetic Technologies Ltd
NAICS : 325414
SIC : 2836
ISIN : AU000000GTG7
Description
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers